Tursky Melinda L, Artuz Crisbel M, Rapadas Melissa, Wittert Gary A, Molloy Timothy J, Ma David D
Blood, Stem Cell, and Cancer Research Programme, St Vincent's Centre for Applied Medical Research and Department of Haematology, St Vincent's Hospital, Sydney, Australia.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Kensington, Australia.
PLoS One. 2025 Feb 26;20(2):e0318300. doi: 10.1371/journal.pone.0318300. eCollection 2025.
Clonal haematopoiesis of indeterminate potential (CHIP) is an aging-associated phenomenon that has recently been correlated with a broad spectrum of human diseases, including haematological malignancy, cytopenia, coronary heart disease, stroke, and overall mortality. CHIP is defined as a somatic variant in blood cells with an allele frequency (VAF) ≥ 0.02, however recent reports show smaller clones are associated with poorer clinical outcome. Error-corrected ultradeep next-generation sequencing (NGS) assays detecting variants < 0.02 VAF also have clinical value for monitoring measurable residual disease (MRD) for myeloid neoplasms. However, limited data are available on optimal parameters, limits of detection, and accuracy of ultra-sensitive detection. We investigated parameters to improve accuracy of Illumina sequencing-by-synthesis method, including read depth, input DNA quantity, and molecular barcoding-based data filtering, while adhering to clinical accreditation criteria. Validation data were generated from reference standards and reference samples from a clinically accredited pathology laboratory. Analytical range measurements included linearity and bias, and precision included repeatability, reproducibility and detection rate. The lower limit of detection was ≥ 0.004 (0.4%) at depth > 3,000 × . Trueness measured using reference standards demonstrated a sensitivity, specificity, positive and negative predictive values, and accuracy of 100%, including FLT3-ITD, and 100% concordance was achieved with reference samples for reported variants and absence of variants. Sequencing blood samples from 383 community-dwelling adults (mean depth 3758×) revealed 2,190 somatic variants/sample, > 99.9% were < 0.02 VAF. Our data including cost-benefit analysis enables pathology and research laboratories to make informed decisions for detection of CHIP (VAF ≥ 0.02), sub-CHIP (VAF 0.01-0.02) and MRD (VAF ≥ 0.004).
不确定潜能的克隆性造血(CHIP)是一种与衰老相关的现象,最近已被证实与多种人类疾病相关,包括血液系统恶性肿瘤、血细胞减少症、冠心病、中风和全因死亡率。CHIP被定义为血细胞中的体细胞变异,其等位基因频率(VAF)≥0.02,然而最近的报告显示,较小的克隆与较差的临床结果相关。检测VAF<0.02的变异的纠错超深度下一代测序(NGS)检测方法对于监测髓系肿瘤的可测量残留病(MRD)也具有临床价值。然而,关于最佳参数、检测限和超灵敏检测准确性的可用数据有限。我们研究了提高Illumina合成测序方法准确性的参数,包括读取深度、输入DNA量和基于分子条形码的数据过滤,同时遵循临床认证标准。验证数据来自临床认可的病理实验室的参考标准和参考样本。分析范围测量包括线性和偏差,精密度包括重复性、再现性和检测率。在深度>3000×时,检测下限≥0.004(0.4%)。使用参考标准测量的真实性显示敏感性、特异性、阳性和阴性预测值以及准确性均为100%,包括FLT3-ITD,并且对于报告的变异和无变异情况,与参考样本的一致性达到100%。对383名社区居住成年人的血样进行测序(平均深度3758×),每个样本发现2190个体细胞变异,>99.9%的变异VAF<0.02。我们的数据包括成本效益分析,使病理和研究实验室能够就CHIP(VAF≥0.02)、亚CHIP(VAF 0.01-0.02)和MRD(VAF≥0.004)的检测做出明智决策。